Premature Ovarian Insufficiency
On this page
Direct answer
Consider premature ovarian insufficiency (POI) in any woman under 40 with amenorrhoea or oligomenorrhoea of at least four months and an FSH above 25 IU/L confirmed on two occasions at least four weeks apart, with a low oestradiol — the ESHRE definition that replaced "premature menopause", because ovarian function in POI is intermittent, not extinguished. It affects roughly 1 per cent of women under 40 and about 1 in 1,000 under 30. Causes cluster into chromosomal (Turner syndrome and mosaicisms), genetic (Fragile X premutation), autoimmune (with thyroid or adrenal autoimmunity), iatrogenic (chemotherapy, pelvic radiotherapy, oophorectomy) and, in the great majority, idiopathic. Two obligations define good care: find the cause with karyotype and FMR1 testing, and replace the missing oestrogen with hormone therapy or the combined pill until the average menopausal age — untreated, these women lose bone density and raise cardiovascular risk decades early. Spontaneous ovulation still occurs, so contraception is needed unless pregnancy is desired.
What you must remember
- Diagnostic triplet: amenorrhoea or oligomenorrhoea for four or more months, before age 40, FSH above 25 IU/L on two tests at least four weeks apart, with low oestradiol; exclude pregnancy first, and check prolactin and TSH.
- Epidemiology numbers: about 1 per cent of women under 40 and 0.1 per cent under 30 — a standard viva statistic.
- Aetiology worth memorising: Turner syndrome and sex chromosome mosaicisms; Fragile X (FMR1) premutation — the single most important mendelian association; autoimmune oophoritis clustering with thyroid or adrenal disease; chemo/radiotherapy (alkylating agents, ovarian-directed radiation); smoking; and idiopathic, the largest group.
- Why not "premature menopause": POI retains intermittent follicular activity — about 5-10 per cent of diagnosed women conceive spontaneously — hence the word insufficiency, and hence contraceptive counselling alongside HRT.
- Workup: karyotype in all (mandatory under 30), FMR1 premutation testing, thyroid antibodies and autoimmune screen, adrenal antibodies where suspicion exists, baseline bone density in long-standing cases.
- HRT rules: oestrogen with progestogen (or the combined oral contraceptive as an alternative) until about age 51; transdermal oestrogen preferred with thrombosis risk factors; the goal is replacing what the ovaries should still be making, to protect bone and cardiovascular health.
- Fertility options: spontaneous pregnancy odds are small; validated options are IVF with donor oocytes, with embryo or oocyte cryopreservation the only guaranteed strategy when iatrogenic POI is foreseeable (oncofertility referral before gonadotoxic therapy).
- Bone and lifestyle: weight-bearing exercise, calcium and vitamin D, smoking cessation, and annual review.
A clinical pathway worth walking
A 32-year-old presents with six months of absent periods, night sweats and infertility treatment fatigue. Pregnancy excluded, prolactin and TSH normal, FSH 42 IU/L with oestradiol in the postmenopausal range — repeat FSH a month later is 38, confirming POI. The cascade that follows is what the exam tests: karyotype (normal 46,XX here), FMR1 premutation testing, positive thyroid antibodies — making this likely autoimmune POI with a need for periodic thyroid and adrenal review. She is counselled on the two facts patients find counterintuitive: her ovaries may still fire occasionally (contraception if not trying to conceive) and she needs oestrogen until 51, not to "tough it out". She chooses a transdermal patch with cyclical progestogen; bone density is assessed and vitamin D corrected. For conception she is offered oocyte donation IVF, which in India proceeds under the ART Regulation Act's altruistic-donation framework, with per-transfer success among the highest in assisted reproduction because the uterus, not the ovary, is the limit. Had she been referred before gonadotoxic chemotherapy years earlier, the correct pathway was fertility preservation before cycle one.
Where students slip
The classic errors: equating POI with menopause and withholding HRT ("she is too young for hormones") — the opposite is true, and untreated early hypo-oestrogenism costs bone; diagnosing on a single FSH without the month-later confirmation; and missing the aetiological workup, especially karyotype in the young and FMR1 counselling, which has reproductive implications for sisters and daughters. A subtler slip is prescribing oestrogen alone in a woman with an intact uterus — the progestogen protects the endometrium exactly as in ordinary HRT. Finally, candidates forget the Turner nuance: mosaic variants may menstruate and present as POI rather than primary amenorrhoea, so karyotyping has a place even after normal puberty.
Frequently asked questions
What are the diagnostic criteria for premature ovarian insufficiency?
Amenorrhoea or oligomenorrhoea for four or more months before age 40, with FSH above 25 IU/L on two occasions at least four weeks apart and low oestradiol.
Which genetic test is indicated beyond karyotype in POI?
Fragile X (FMR1) premutation testing, the most important mendelian association, with implications for relatives.
Can a woman with POI conceive naturally?
Yes — intermittent ovarian function means about 5-10 per cent conceive spontaneously, so contraception is needed if pregnancy is not desired; donor oocyte IVF is the reliable fertility option.
Until what age should HRT be continued in POI?
Until the average age of natural menopause, about 51 years, to protect bone density and cardiovascular health.
Which chemotherapy agents are most gonadotoxic?
Alkylating agents such as cyclophosphamide, with risk rising cumulatively with dose and patient age — hence fertility preservation counselling before treatment.